Investors
Backing Science, Building Value, Saving Lives.
Join a company redefining oncology through biology and engineering
Why investing in AlphaOnco Group – Nanobacterie?
Video presentation:
Dedicated team mixing scientific and business skills, located in Paris, Zurich & Luxembourg
Access to top experts in medicine (urology), scientific matters (biology, physico-chemistry, physics, chemistry, microbiology), regulatory matters, financials, design of clinical trials.
Proven preclinical efficacy on various tumor types
Magnetosome fabrication & therapy under controll.
Safe treatment backed by strong peer validation
40+ international peer-reviewed publications.
Project validated by the funding of 3 Eurostars projects.
A health challenge
Prostate cancer is a health challenge, necessitating an efficient, safe and accessible treatment such as the one developed by AlphaOnco.
Strong IP portfolio serving the Group’s strategy
AlphaOnco Group’s treatment and activity protected or under protection worldwide through 13 patent families covering the magnetosome-based product, various methods of treatment & magnetosome production process.
Invest
Investor Relations Contact
Edouard Alphandery
CEO
AlphaOnco
edouard.alphandery@alphaonco.fr
Access our investor documentation
deck, teaser, executive summary, movie presenting the project.
Please complete the form below to receive your personalized access credentials.
They already trust us
